TICKERNERD
Menu
IMMXIMMXHealthcare · Biotechnology

IMMX Stock Forecast: Immix Biopharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
−4.41% on the day

The 7 Wall Street analysts covering Immix Biopharma, Inc. hold a median 12-month price target of $22 — +81.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$868.5M
Ticker Nerd rank
34 / 100
Median analyst target
$22
Analysts covering
7
Revenue$0.0
Operating income−$12.5M
Net income−$11.6M
Free cash flow−$11.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.2%
1M
+5.7%
YTD
+132.1%
1Y
+446.8%
From 52W high
−16.1%
From 52W low
+519.4%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMMX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immix Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Quality
62
Value
62
Size
46
Volatility
45
Revisions
31
Issuance
28
Growth
27
Accruals
21

Momentum (94): The shares have been drifting up relative to others.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26IMMXHigh $27Median $22Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $13Median $22High $27

The green dot is the last close — the median target sits +81.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026Morgan StanleyMaintainsOverweight$20 → $19
10 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $25
22 July 2026NeedhamInitiatesBuy—
22 July 2026NeedhamInitiatesBuy$21
18 June 2026B of A SecuritiesInitiatesBuy—
18 June 2026B of A SecuritiesInitiatesBuy$27
17 June 2026LifeSci CapitalInitiatesOutperform—
22 May 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
30 Mar 2026MizuhoMaintainsOutperform—
27 Mar 2026CitizensReiteratesMarket Outperform—
27 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026Morgan StanleyInitiatesOverweight—
9 Mar 2026CitizensInitiatesMarket Outperform—
9 Feb 2026MizuhoInitiatesOutperform—
9 Dec 2025HC Wainwright & Co.MaintainsBuy—
12 Sept 2025HC Wainwright & Co.MaintainsBuy—
4 June 2025HC Wainwright & Co.ReiteratesBuy—
10 Feb 2025HC Wainwright & Co.ReiteratesBuy—
6 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMMX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMMX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Immix Biopharma, Inc. returned +446.8% against +17.5% for the S&P 500, dividends included.

IMMX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Oct 25Jan 26Apr 26Jul 26IMMXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Immix Biopharma, Inc. (IMMX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.6×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
3.8×

Cheaper than 27% of US stocks

EV / EBITDA
−15.4×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−34.2%

Higher than 26% of US stocks

Return on assets
−20.5%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immix Biopharma, Inc. (IMMX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immix Biopharma, Inc. has a market value of $868.5M and an enterprise value of $637.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$39.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$39.1M.

  • Shares outstanding: 71.2M.

  • Trailing P/E: −13.6×; forward P/E: −13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Immix Biopharma, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

IMMX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMMXImmix Biopharma, Inc.$868.5M
34
GERNGeron Corp.$864.7M
52
ARDXArdelyx, Inc.$869.8M
50
TBPHTheravance Biopharma, Inc.$856.6M
89
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
AVTXAvalo Therapeutics, Inc.$847.4M
38
WVEWave Life Sciences, Inc.$883.0M
14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immix Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMMX news & analysis

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Business Wire · 6 Aug 2026negative

Business Wire announced that IMMX investors have the opportunity to join a fraud investigation into Immix Biopharma, Inc. being conducted by SBS Law. The notice is directed at shareholders of the company.

Why it matters — Immix Biopharma watchers would care because a law firm is investigating potential fraud involving the company, which raises legal and reputational concerns for shareholders.

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 4 Aug 2026neutral

Immix Biopharma announced it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026 in New York, NY.

Why it matters — The conference gives IMMX a platform to conduct institutional investor meetings at a major healthcare forum, which an IMMX watcher would likely want to track.

FAQ

Frequently asked questions about IMMX stock

What is the IMMX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Immix Biopharma, Inc. have a median 12-month price target of $22, with estimates ranging from $13 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMMX stock a buy right now?

Of the 7 analysts covering Immix Biopharma, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immix Biopharma, Inc. 34 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMMX?

As at 12 Sept 2026, Immix Biopharma, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will IMMX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +81.2% from the last close, and Ticker Nerd's factor model ranks Immix Biopharma, Inc. 34 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMMX stock forecast for 2030?

No analyst covering Immix Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $27 over the next 12 months.

How has IMMX stock performed over the past year?

Immix Biopharma, Inc. returned +446.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immix Biopharma, Inc. do?

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers.

What is the latest news on IMMX?

The most recent item we track (Business Wire, 6 Aug 2026): "IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law". Business Wire announced that IMMX investors have the opportunity to join a fraud investigation into Immix Biopharma, Inc. being conducted by SBS Law. The notice is directed at shareholders of the company.

Company

About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.

CEO Dr. Ilya Rachman M.B.A., M.D., Ph.D. · 21 employees · United States · https://www.immixbio.com